The Scientific World Journal

The Scientific World Journal / 2010 / Article

Review Article | Open Access

Volume 10 |Article ID 475156 | https://doi.org/10.1100/tsw.2010.213

Martina Victoria Schmidt, Bernhard Brüne, Andreas von Knethen, "The Nuclear Hormone Receptor PPARγ as a Therapeutic Target in Major Diseases", The Scientific World Journal, vol. 10, Article ID 475156, 17 pages, 2010. https://doi.org/10.1100/tsw.2010.213

The Nuclear Hormone Receptor PPARγ as a Therapeutic Target in Major Diseases

Academic Editor: Martin Goette
Received29 Jul 2010
Revised12 Oct 2010
Accepted25 Oct 2010

Abstract

The peroxisome proliferator-activated receptor γ (PPARγ) belongs to the nuclear hormone receptor superfamily and regulates gene expression upon heterodimerization with the retinoid X receptor by ligating to peroxisome proliferator response elements (PPREs) in the promoter region of target genes. Originally, PPARγ was identified as being essential for glucose metabolism. Thus, synthetic PPARγ agonists, the thiazolidinediones (TZDs), are used in type 2 diabetes therapy as insulin sensitizers. More recent evidence implied an important role for the nuclear hormone receptor PPARγ in controlling various diseases based on its anti-inflammatory, cell cycle arresting, and proapoptotic properties. In this regard, expression of PPARγ is not restricted to adipocytes, but is also found in immune cells, such as B and T lymphocytes, monocytes, macrophages, dendritic cells, and granulocytes. The expression of PPARγ in lymphoid organs and its modulation of macrophage inflammatory responses, lymphocyte proliferation, cytokine production, and apoptosis underscore its immune regulating functions. Moreover, PPARγ expression is found in tumor cells, where its activation facilitates antitumorigenic actions. This review provides an overview about the role of PPARγ as a possible therapeutic target approaching major, severe diseases, such as sepsis, cancer, and atherosclerosis.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views946
Downloads1865
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.